Christos Argyropoulos MD, PhDFeb 9, 2023

This supplemental fig from EMPA-KIDNEY is particularly useful to all of us in the US who have to deal with insurance companies : #flozin (SGLT2i) may work even if not on RAS therapy. Caveat emptor applies (85% of participants were on RASi subgroup analysis etc)
#CKD #nephmastodon #cardiomastodon #endomastodon
@Kidney_boy @hswapnil @edgarvlermamd @mike_johansen

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/

Empagliflozin in Patients with Chronic Kidney Disease

This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression.We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus ...

PubMed Central (PMC)
Christos Argyropoulos MD, PhDJan 6, 2023
Ok #nephmastodon, #endomastodon , #cardiomastodon and all fellow travelers in #medmastodon.
Get your manuscripts ready!
The Journal of Clinical Medicine's invitation for articles about #CKD in #Diabetes is out. Deadline to send us your killer paper is September 15th 2023. Will you miss out on the fun?
Christos Argyropoulos MD, PhDDec 28, 2022
Population studied in the finerenone trials #FIGARODKD and #FIDELIODKD in a snapshot.
(Share with everyone who questions how widely applicable these trials are in #DKD #diabetes #CKD #NephMastodon #EndoMastodon #cardiomastodon
Christos Argyropoulos MD, PhDNov 29, 2022
So much information in the supplement of the #Fidelity meta-analysis
https://academic.oup.com/eurheartj/article/43/6/474/6433104?login=false#supplementary-data
➡️This the risk profile of the participants I treat.
➡️It does not matter what their characteristics are, or whether they take other drugs #flozins #GLP1RA.
#Finerenone works the same!
#nephmastodon #endomastodon #cardiomastodon
#ckd #diabetes #cvd
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

AbstractAims. The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes and chronic kidney disease (CKD) examined cardiovascular and

OUP Academic
Christos Argyropoulos MD, PhDNov 28, 2022
When I read this paper, I had nightmares that I joined a practice which uses only 5 mg of #lisinopril.
https://www.mayoclinicproceedings.org/article/S0025-6196(22)00447-5/pdf
#ckd #diabetes #nephmastodon #endomastodon #ARB #ACEi #cardiomastodon
1/3 of pts were on appropriate dose!!
(Nephrologists didn't do better than the other specialties)
Christos Argyropoulos MD, PhDNov 28, 2022

We should talk about eGFR triggered Nephrology referrals in the elderly.

#CKD #nephmastodon #EndoMastodon #cardiomastodon
Is the solution to look beyond eGFR, i.e. risk stratify with albuminuria+eGFR / KFRE + screening labs as suggested by NIDDK ?
@hswapnil @edgarvlermamd @mike_johansen @jsussman

Christos Argyropoulos MD, PhDNov 27, 2022
This is a very nice review of non-albuminuric diabetic kidney disease (or chronic kidney disease without albuminuria) in patients with diabetes
https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-021-00612-9
#FOAMED #nephmastodon #cardiomastodon #chronickidneydisease #diabetes
#ckd #endomastodon
Update on pathogenesis and diagnosis flow of normoalbuminuric diabetes with renal insufficiency - European Journal of Medical Research

In recent decades, the prevalence of diabetic kidney disease has remained stable and appears to be a wide heterogeneity. Normoalbuminuric diabetes with renal insufficiency, which is characterized by a decline in the glomerular filtration rate in the absence of albuminuria, has been identified as an albuminuria-independent phenotype of diabetic kidney disease. Epidemiological data demonstrate that normoalbuminuric phenotype is prevalent. Compared to albuminuric phenotype, normoalbuminuric phenotype has distinct clinical characteristics and a wide heterogeneity of pathological features. Currently, the pathogenesis of normoalbuminuric phenotype remains unclear. Additionally, the flow of diagnosing normoalbuminuric phenotype is not perfect. In this article, we review the latest studies addressing the epidemiology, clinical characteristics, and pathology of normoalbuminuric phenotype. Based on the studies of clinical features and renal histopathologic changes, we attempt to propose an underlying pathogenesis model and a flow chart for diagnosing normoalbuminuric phenotype.

BioMed Central